NCT00752518View on ClinicalTrials.gov

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

January 31, 2006

Conditions
RefractoryMultiple MyelomaRelapse
Interventions
DRUG

bortezomib

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT00752518 - A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter